The Panic-Proof Portfolio (Stockchase Research)Levi Strauss & Co.LEVITOP PICKOct 13, 2020

They reported a mixed quarter in early August with light sales in direct to consumer. The bottom line beat mostly from tariff refunds. Also, guidance was disappointing. Shares fell, but have since rallied over 20% from that low. It's still cheap at 14x PE, pays a 2.8% dividend and buying lots of shares.

They just reported a mixed quarter with a small revenue miss that was driven by currency fluctuations while organic growth was in line and delivered a large EPS beat due to tariff refunds. They raised their full-year forecast though a little less than expected. He likes it.

They report Tuesday. Even if they report good numbers, will it matter? They boast good growth and a 3% dividend.

Today they reported a modest top and bottom line beat, earnings forecast was a little light though the revenue forecast was solid. They have expanded well beyond jeans, but are hit by Trump's tariffs. Things will run their course. 

They report Thursday. Is reliable, despite tariffs. It hit a 52-week high today, and is +41% this year. He expects another good quarter.

They delivered a solid quarter, sales strong with an earnings beat thanks to higher than expected margins. Guidance is unchanged. Shares are down 45% from highs last June, but showed life at today's close.

They report Monday. The last quarter when they offered guidance, the stock got hammered. Apparel has been a mixed bag.

It reported after the bell superb 12% YOY sales growth, strength in the Americas, Europe and direct to consumer channels. They beat gross margins, but due to higher expenses, they delivered a modest earnings beat. Their full-year forecast was a little mixed, but overall good.

They just reported a minor sales miss but an earnings beat and cut their full-year revenue forecast though asserted their earnings would meet the midpoint of previous guidance. Europe and direct-to-consumer are strong, but Asian and America are weaker.

They just reported a slight revenue, but a strong earnings beat but didn't adjust their guidance. Shares are up 40% this year.

Could benefit from the weight-loss drug boom, because those who take those drugs will need need jeans. But the company reported a weak quarter and cut guidance.

Today, it reported an earnings and sales beat, but shares fell 16%. They lowered their full-year gross margin outlook a lot, but didn't touch earnings guidance. Also, they forecast a sales decline around 8-12% this quarter.